However, our results indicate CML-iPSCs are sensitive to IM treatment, reflected through their increased differentiation when treated, highlighting a role for BCR-ABL in the stemness properties of CML-iPSCs. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.